IVIG Not Working for CIDP? Here's What Usually Happens Next

IVIG stopping or seeming to stop working does not automatically mean the treatment has failed. For many people with CIDP, symptoms return because the dose needs adjustment, infusions are spaced too far apart, the disease has become more active, or the nerves need more time to recover. Before changing treatment, neurologists usually reassess symptoms, strength, and treatment response to understand why IVIG is no longer providing the same benefit. Depending on those findings, the treatment plan may be adjusted, another therapy may be added, or a different approach may be considered.

For many patients, this is one of the most worrying moments after diagnosis. Symptoms that had started to improve may slowly return, walking may become harder again, or weakness may appear before the next scheduled infusion. While these changes can feel discouraging, they are not uncommon in CIDP and they do not always mean IVIG has stopped working permanently.

Why IVIG May Seem to Stop Working

There is no single reason why IVIG may appear to stop working. In many cases, the treatment itself has not failed. Instead, the immune activity causing CIDP has changed, the treatment schedule may no longer be the right fit, or the nerves have not recovered enough to keep up with ongoing damage.

Neurologists usually look for the underlying reason before recommending any major changes. The goal is to determine whether the current IVIG plan can be adjusted or whether another treatment strategy is more appropriate.

The most common reasons include:

The effects of IVIG wear off before the next infusion

Some people notice that their strength gradually declines a few days before their next scheduled infusion. This is often called a wearing-off effect or treatment-related fluctuation. Rather than meaning IVIG has stopped working completely, it may indicate that the interval between infusions is too long or that the maintenance dose needs adjustment.

The disease has become more active

CIDP is a chronic autoimmune condition, and disease activity can change over time. Even while receiving IVIG, the immune system may become more active, causing weakness, numbness, or balance problems to return. This does not necessarily mean IVIG is ineffective, but it may mean the current treatment plan is no longer providing enough immune control.

The current dose may no longer be enough

IVIG treatment is highly individualized. Factors such as body weight, disease severity, symptom progression, and response to previous infusions all influence the maintenance dose. As the condition changes, some patients may require adjustments to either the dose or the infusion schedule to maintain symptom control.

Nerve healing takes longer than expected

IVIG helps reduce the immune attack on the nerves, but it cannot immediately repair nerve damage that has already occurred. If significant nerve injury developed before treatment began, recovery may continue slowly over several months. During this time, improvement may appear to plateau even though the treatment is still controlling inflammation.

Another condition may be contributing to symptoms

Not every increase in weakness or numbness is caused by CIDP alone. Other medical conditions, medication side effects, nutritional deficiencies, or progression of unrelated nerve disorders can produce similar symptoms. When recovery does not follow the expected pattern, neurologists may recommend additional testing to confirm that CIDP remains the primary cause of the symptoms.

How Do Doctors Find Out Why IVIG Isn't Working?

The first step is rarely switching treatments. Instead, neurologists try to understand why symptoms have changed.

During a follow-up evaluation, they may assess:

• Whether muscle strength has declined since the last visit
• Whether numbness, tingling, or balance problems are progressing
• When symptoms return in relation to the IVIG infusion schedule
• How daily activities such as walking, climbing stairs, or using the hands have changed
• Whether any new medical conditions or medications could be affecting symptoms

Depending on the findings, additional tests such as nerve conduction studies, electromyography (EMG), blood tests, or imaging may be repeated to compare the current condition with earlier results. These tests help determine whether the disease is becoming more active, whether treatment adjustments are needed, or whether another diagnosis should be considered.

Rather than assuming IVIG has failed, neurologists use this information to identify the most appropriate next step.

This is the section where the blog differentiates itself from existing content. Most articles jump straight to "switch treatments." Instead, we should show the clinical decision pathway that neurologists actually follow.

What Usually Happens Next?

When IVIG no longer seems to control CIDP symptoms, neurologists rarely stop treatment immediately. Instead, they work through a series of steps to understand what's causing the change and choose the safest, most effective next option.

The pathway often looks like this:

Step 1: Reassess Symptoms and Disease Activity

The first step is determining whether symptoms have genuinely worsened or whether they fluctuate between infusions.

The neurologist may ask questions such as:

• When did symptoms begin to return?
• Do they improve after each infusion?
• Is weakness affecting new parts of the body?
• Have balance, walking, or hand function changed?
• Are daily activities becoming more difficult?

Comparing current symptoms with previous visits helps identify whether the disease is becoming more active or whether the treatment schedule simply needs adjustment.

Step 2: Review the Current IVIG Plan

Many people remain on IVIG successfully for years, but the maintenance plan often requires adjustments over time.

The neurologist may review:

• The current IVIG dose
• How often infusions are given
• How long symptom relief lasts after each infusion
• Side effects that might limit treatment
• Whether infusions are being completed as planned

Sometimes, a relatively small adjustment to the dose or infusion interval is enough to restore symptom control.

Step 3: Repeat Testing if Needed

If symptoms continue to worsen despite treatment adjustments, additional testing may help clarify what's happening.

Depending on the situation, this may include:

• Repeat nerve conduction studies (NCS)
• Electromyography (EMG)
• Blood tests to rule out other conditions
• MRI or other imaging in selected cases

These tests help determine whether ongoing nerve damage is occurring, whether the diagnosis still fits CIDP, or whether another neurological condition should be considered.

Step 4: Decide Whether Another Treatment Is Needed

If IVIG adjustments do not provide enough improvement, the neurologist may recommend another treatment strategy.

The decision depends on several factors, including:

• How active the disease is
• How much disability is developing
• Previous response to treatment
• Overall health and other medical conditions
• Personal treatment goals and lifestyle

For some people, IVIG remains part of the treatment plan with modifications. For others, adding or switching therapies may offer better long-term disease control.

What Treatments May Be Considered If IVIG Isn't Enough?

When IVIG no longer provides adequate symptom control, several other evidence-based treatment options are available. The most appropriate choice depends on the individual's symptoms, response to previous treatments, and overall health.

Plasma Exchange (Plasmapheresis)

Plasma exchange removes antibodies and other immune proteins from the bloodstream that contribute to nerve inflammation. Because it often works quickly, it may be recommended when symptoms worsen rapidly or when a faster response is needed.

However, its benefits are usually temporary, and repeated treatments are often necessary to maintain improvement.

Corticosteroids

Corticosteroids help reduce the immune system's attack on peripheral nerves. Some patients respond well to steroids alone, while others may receive them alongside IVIG to improve disease control or reduce the need for frequent infusions.

Because long-term steroid use can cause significant side effects, neurologists carefully weigh the potential benefits against the risks.

Subcutaneous Immunoglobulin (SCIg)

Some patients who respond well to IVIG but experience wearing-off symptoms may benefit from switching to SCIg. Instead of receiving large doses every few weeks, SCIg delivers smaller doses more frequently under the skin, helping maintain more consistent immunoglobulin levels.

This approach may reduce treatment-related fluctuations for selected patients.

Immunosuppressive or Immunomodulatory Therapy

When CIDP remains active despite standard treatments, medications that modify the immune system may be considered. These therapies are typically reserved for patients whose disease is difficult to control or who cannot tolerate first-line treatments.

Because these medications affect the immune system differently, careful monitoring is usually required.

Clinical Trials

Researchers continue to study new therapies that may improve symptom control, reduce treatment burden, or provide additional options for people whose CIDP remains difficult to manage. Depending on eligibility and previous treatment history, participation in a clinical trial may be another option to discuss with a neurologist.

When Should Someone Contact Their Neurologist?

Not every change in symptoms is an emergency, but new or worsening weakness should never be ignored. Early assessment gives the neurologist the best opportunity to adjust treatment before additional nerve damage occurs.

A follow-up appointment should be arranged if:

• Weakness returns sooner than usual after an IVIG infusion
• Walking, climbing stairs, or standing becomes noticeably more difficult
• Numbness or tingling continues to spread
• Balance problems increase or falls become more frequent
• Hand weakness begins to interfere with everyday tasks
• Symptoms continue to worsen despite receiving IVIG as scheduled

Keeping a simple symptom diary between infusions can also be helpful. Recording when symptoms improve, when they begin to return, and how they affect daily activities gives the neurologist a clearer picture of how well the current treatment plan is working.

Does IVIG Always Stop Working Over Time?

No. Many people with CIDP continue to benefit from IVIG for years. Others may need occasional adjustments to their dose or infusion schedule as the disease changes over time.

Every person's response is different. Some achieve long periods of stable disease with regular maintenance infusions, while others experience periods where symptoms become more active and require changes to their treatment plan.

Rather than asking whether IVIG has "failed," neurologists usually ask a different question:

Is the current treatment plan still controlling the disease as effectively as it should?

That distinction is important because many patients regain good symptom control after relatively small adjustments, while others may benefit from adding or changing therapies.

Perfect. For this blog, the FAQ section should be search-driven, not filler. These are the questions that repeatedly appear in Google's PAA, patient forums, and CIDP communities.

Frequently Asked Questions

How do I know if IVIG is no longer working?

Possible signs include increasing muscle weakness, worsening numbness or tingling, more difficulty walking, frequent falls, or symptoms returning earlier between infusions. These changes should be discussed with a neurologist, who can determine whether the current treatment plan is still providing adequate disease control.

Can CIDP relapse while receiving IVIG?

Yes. Although IVIG helps control the immune attack on the nerves, some people experience relapses or treatment-related fluctuations during long-term management. Returning symptoms should be evaluated promptly so that treatment can be adjusted if necessary.

Is permanent nerve damage more likely if IVIG isn't working?

Persistent inflammation over time can increase the risk of permanent nerve damage. This is why new or worsening symptoms should be evaluated as early as possible. Prompt treatment adjustments may help reduce ongoing nerve injury and preserve long-term function.

Should IVIG be stopped if symptoms come back?

No. IVIG should never be stopped or changed without medical advice. Symptoms returning does not necessarily mean the treatment is ineffective. A neurologist will usually review symptom progression, examine muscle strength, and decide whether adjustments to the current treatment plan or another therapy are appropriate.

Can someone switch from IVIG to another treatment?

Yes. If IVIG is no longer providing adequate symptom control or is causing unacceptable side effects, a neurologist may recommend another treatment approach. Depending on the individual's condition, options may include SCIg, plasma exchange, corticosteroids, or other immune-modifying therapies.

Final Thoughts

Seeing symptoms return after IVIG can be frustrating, but it does not automatically mean the treatment has failed. In many cases, the underlying issue is that the disease has changed or the current treatment plan needs adjustment rather than replacement.

CIDP is a chronic condition that often requires ongoing monitoring and individualized care. Regular follow-up, timely reporting of new symptoms, and periodic reassessment allow treatment to be adapted as the disease changes over time. With the right adjustments, many people continue to maintain strength, mobility, and independence even if their treatment plan evolves.